Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.
about
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainB Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsNew insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathyThe importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathyProgressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapiesIlluminating viral infections in the nervous systemProgressive Multifocal Leukoencephalopathy-Associated Mutations in the JC Polyomavirus Capsid Disrupt Lactoseries Tetrasaccharide c BindingViral miRNAs in plasma and urine divulge JC polyomavirus infection.Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient.Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy.JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route.JC polyomavirus attachment, entry, and trafficking: unlocking the keys to a fatal infection.JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence.Orderly Steps in Progression of JC Virus to Virulence in the Brain.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.5-HT2 receptors facilitate JC polyomavirus entry.Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab.The human alpha defensin HD5 neutralizes JC polyomavirus infection by reducing endoplasmic reticulum traffic and stabilizing the viral capsid.Circulating human microRNAs are not linked to JC polyomavirus serology or urinary viral load in healthy subjects.Immune surveillance and response to JC virus infection and PML.Reactivation of human polyomaviruses in immunocompromised states.The link between VLA-4 and JC virus reactivation.Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.The human JC polyomavirus (JCPyV): virological background and clinical implications.Pathogen manipulation of B cells: the best defence is a good offence.Immunology of progressive multifocal leukoencephalopathy.B cells and progressive multifocal leukoencephalopathy: search for the missing linkRisk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.Clonal immortalized human glial cell lines support varying levels of JC virus infection due to differences in cellular gene expression.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.Efficient propagation of archetype JC polyomavirus in COS-7 cells: evaluation of rearrangements within the NCCR structural organization after transfection.JC polyomavirus viremia and progressive multifocal leukoencephalopathy in human leukocyte antigen-sensitized kidney transplant recipients desensitized with intravenous immunoglobulin and rituximab.MiR-126: a novel route for natalizumab action?Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies?COS-7-based model: methodological approach to study John Cunningham virus replication cycle.JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Viral microRNA effects on persistent infection of human lymphoid cells by polyomavirus SV40.
P2860
Q24619923-361CBA53-DB50-49CD-B5C6-865ABFAB9B59Q26770664-9878C90B-E7B4-4663-A518-83623DB15EF0Q26822247-92D76933-F8DE-422B-B5E9-D4F05E17B2B2Q26859307-16C08561-6F88-4D54-892A-092C315E6E32Q27028025-B4B3BF0C-AF55-4A51-944E-073EBFDD8FE0Q27310280-A2C46920-C6C3-482B-915E-BB173C10A456Q27678593-94AD5C87-D65F-4D90-BCF5-FFFC77C2A6CBQ34208184-38896753-0FC4-4671-930F-95B540C1161AQ34230150-AB75684A-E1FD-4BD3-844E-BF3B0349F427Q34729712-552FA617-9236-4E71-9F17-7F477F402D43Q34991069-3E04322F-96BF-414E-8D34-6A78605C2E5DQ35033782-3292E87D-27E4-4476-A3EE-7D136F7CEBF2Q35586120-57D603AF-1BB9-49B1-8037-F8311963CE54Q35874385-7E275FFB-B4D2-4EE7-AD1C-D5F390923CD7Q36044561-574D3D0A-3358-4306-A040-5BFD85D4A939Q36767522-989B53A1-4E25-4DA5-AAA1-0FDCBA9236BEQ37336799-2B3A2940-BE2F-4A35-9592-064713D94CF3Q37371745-9BACDCDE-688B-4985-9727-650F031B5F61Q37547573-9FAD219C-4A93-4180-BD07-7FF4829FA5B3Q37621983-2E9311C2-5BD3-47A7-8810-15CE8EA21658Q37678580-31098AFC-998D-43B5-97D4-EF41ABB8D244Q37725435-AE4198CC-753E-44FE-9E9C-FA0517554EA7Q37965603-F399FD5F-9F2D-4C9D-99F0-61DADF65539FQ37980042-4637B4DB-ADC4-4D5E-BD10-8A1239C92B49Q38115572-503B915B-B002-4577-9195-8D68D4E7E36DQ38346756-CE51E04A-2CC4-49ED-880E-3C81645B8A7CQ38367755-C3D889C5-B8E8-440C-81FB-20DA05DB6D14Q38515349-761FD144-EE10-413E-986C-408501022100Q38591114-07AE48D9-8921-4127-BC70-FB1D3D830143Q38801394-297B7ED9-F19D-4FBE-9C64-ED4B2D47C59DQ39093837-E56C67F2-8207-4021-931B-9579ADE761AEQ40039520-D3AA63FA-9E2F-4F0F-AD29-00F5961E2BACQ40051729-59A9FA50-126B-452D-8797-53C773AD2FB1Q40965913-67085567-455D-4F32-8C4B-41B637372B6BQ42233577-398E5E92-CF69-4D74-A012-C7BDA00ECDE7Q45182536-B347D369-E8A8-4E99-A0A3-49527CCCBADBQ48103751-94FBA73A-67FB-4775-9AD0-77D434D717DAQ48246057-7268F477-E7A3-4496-A8F3-6E7E17FA5168Q49884884-9BCD4D1C-B82A-4330-A173-01293D8C9B75Q50047202-A344F2C5-18C4-4BAA-9384-32F2BA540B36
P2860
Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@ast
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@en
Human polyomavirus JC
@nl
type
label
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@ast
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@en
Human polyomavirus JC
@nl
prefLabel
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@ast
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@en
Human polyomavirus JC
@nl
P2860
P356
P1476
Human polyomavirus JC (JCV) in ...... cross the blood-brain barrier.
@en
P2093
Moti L Chapagain
Vivek R Nerurkar
P2860
P304
P356
10.1086/653823
P407
P577
2010-07-01T00:00:00Z